Yoshiyama M, de Groat W C
Department of Pharmacology, University of Pittsburgh School of Medicine, PA 15261, USA.
Neuroscience. 2005;132(4):1017-26. doi: 10.1016/j.neuroscience.2005.01.041.
Effects of i.c.v. and i.t. administration of (3SR,4aRS,6RS,8aRS)-6-[2-(1H-tetrazol-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (LY215490), a competitive alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor antagonist and MK-801, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist on the micturition reflex were evaluated in urethane-anesthetized rats, to determine if glutamatergic mechanisms in brain as well as spinal cord are important for the control of micturition. I.c.v. or i.t. injection of LY215490 in low doses (0.01-0.03 microg) did not change rhythmic bladder or external urethral sphincter (EUS) electromyogram (EMG) activity during continuous cystometrograms (CMGs; 0.21 ml/min), whereas higher doses (0.1-1 microg) markedly suppressed these responses. During single CMGs (0.04 ml/min), 0.1-1 microg i.c.v. or 0.1-10 microg i.t. doses increased volume threshold and pressure threshold for inducing micturition, and decreased bladder contraction amplitude and voiding efficiency. MK-801 in low doses (0.6 microg i.c.v. or 0.6-1.8 microg for i.t.) did not change bladder contraction amplitude or EUS EMG activity during continuous CMGs, whereas higher doses 6-60 microg markedly suppressed these responses. During single CMGs, MK-801 (6-60 microg i.c.v. or 60 microg i.t.) increased volume threshold and pressure threshold, and decreased voiding efficiency and bladder contraction amplitude. Pretreatment i.c.v. with MK-801 in a dose 1.8 microg which alone had little effect on bladder contraction amplitude and EUS EMG activity, markedly enhanced depressant effects of LY215490 (0.03 microg i.c.v.) on these responses. Administration of same doses of drugs by i.t. route did not elicit a similar synergistic interaction. These data indicate that in urethane-anesthetized rats glutamatergic mechanisms in brain and spinal cord are essential for controlling micturition and that interactions between AMPA and NMDA glutamatergic transmission are important at supraspinal but not spinal sites.
在乌拉坦麻醉的大鼠中评估了脑室内(i.c.v.)和鞘内(i.t.)注射竞争性α-氨基-3-羟基-5-甲基异恶唑-4-丙酸(AMPA)受体拮抗剂(3SR,4aRS,6RS,8aRS)-6-[2-(1H-四氮唑-5-基)乙基]十氢异喹啉-3-羧酸(LY215490)和非竞争性N-甲基-D-天冬氨酸(NMDA)受体拮抗剂MK-801对排尿反射的影响,以确定脑和脊髓中的谷氨酸能机制对排尿控制是否重要。在连续膀胱测压(CMGs;0.21 ml/min)期间,脑室内或鞘内注射低剂量(0.01 - 0.03 μg)的LY215490不会改变节律性膀胱或尿道外括约肌(EUS)肌电图(EMG)活动,而较高剂量(0.1 - 1 μg)则会显著抑制这些反应。在单次CMGs(0.04 ml/min)期间,脑室内注射0.1 - 1 μg或鞘内注射0.1 - 10 μg剂量会增加诱发排尿的容量阈值和压力阈值,并降低膀胱收缩幅度和排尿效率。低剂量的MK-801(脑室内注射0.6 μg或鞘内注射0.6 - 1.8 μg)在连续CMGs期间不会改变膀胱收缩幅度或EUS EMG活动,但较高剂量6 - 60 μg会显著抑制这些反应。在单次CMGs期间,MK-801(脑室内注射6 - 60 μg或鞘内注射60 μg)会增加容量阈值和压力阈值,并降低排尿效率和膀胱收缩幅度。预先脑室内注射1.8 μg剂量的MK-801(其单独对膀胱收缩幅度和EUS EMG活动影响很小)会显著增强LY215490(脑室内注射0.03 μg)对这些反应的抑制作用。通过鞘内途径给予相同剂量的药物不会引发类似的协同相互作用。这些数据表明,在乌拉坦麻醉的大鼠中,脑和脊髓中的谷氨酸能机制对于控制排尿至关重要,并且AMPA和NMDA谷氨酸能传递之间的相互作用在脊髓以上部位而非脊髓部位很重要。